Alaa Elkalamawi

Alaa Elkalamawi

Auto-generated profile, based on publicly available information

Alaa Elkalamawi

Epidemiology- Medicine, Lincoln University, Kota Bharu, Malaysia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Qatar Medical Journal
Verified
Journal Article
Open access
MDMoataz Derbala
Moataz Derbala
IOIbrahim M. Obeidat
Ibrahim M. Obeidat
RARaya Abualsuod
Raya Abualsuod
MDMahmoud Draidi
Mahmoud Draidi
NSNagah Selim
Nagah Selim
AEAlaa Elkalamawi
Alaa Elkalamawi
Background : Metabolically-dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in populations with metabolic risk factors, and the liver fibrosis stage is the main determinant of long-term outcomes. The Fibrosis-4 (FIB-4) index is widely recommended as a first-line noninvasive test for fibrosis risk stratification; however, its diagnostic performance may vary across populations. Objective : To evaluate the diagnostic performance of the FIB-4 index for detecting advanced liver fibrosis in Qatari residents with MASLD, using liver biopsy as the primary reference standard and FibroScan as a secondary comparator. Methodology : This retrospective, cross-sectional diagnostic accuracy study included adults with MASLD evaluated at Hamad Medical Corporation in Qatar between January 2023 and December 2024. FIB-4 was calculated from routine laboratory parameters, and fibrosis was staged using the METAVIR (Meta-Analysis of Histological Data in Viral Hepatitis) scoring system. It is a histological scoring system used to grade necroinflammatory activity (A0–A3) and stage liver fibrosis (F0–F4). Advanced fibrosis was defined as METAVIR stage ≥F3. Diagnostic performance metrics and the area under the receiver operating characteristic curve (AUROC) were calculated at established cut-offs. Results : A total of 117 patients were included; 74 patients (63.2%) underwent liver biopsy, and 91 patients (77.7%) underwent FibroScan assessment. Advanced fibrosis was present in 21 patients (17.9%) on biopsy. At a FIB-4 cut-off of 1.3, sensitivity and specificity for detecting advanced fibrosis were 66.7% and 67.9%, respectively, compared with liver biopsy, with an overall accuracy of 67.6% and a negative predictive value of 83.7%. The AUROC for FIB-4 was 0.76. Conclusion : FIB-4 can be used as a first-line, accountable screening tool, followed by another confirmatory tool in high-risk patients.